Announcing a special webinar by the Praziquantel Consortium for Children and the GHIT Fund .
Click here for more information about webins
Phase III study of schistosomiasis pediatric drug "Arapraziquantel" completed-Toward a new treatment option for preschool children suffering from schistosomiasis-
Date and time: Thursday, December 9, 2021 Japan time 5:00 pm – 6:30 pm
Language: Japanese, English (with simultaneous interpretation)
Participation fee: Free / Language: 80% Japanese and 20% English (no translation available)
Click here to register
The webinar is the pediatric Praziquantel Consortium following the completion of Phase III trials of the pediatric Praziquantel Consortium, a new therapeutic candidate for preschool children suffering from schistosomiasis. It is co-sponsored by GHIT Fund and GHIT Fund. In this webinar, the background of the establishment of the pediatric Praziquantel Consortium, which started its activities in 2012, the development path and development secrets of pediatric therapeutic agents, clinical trial results, expected impact on new pediatric therapeutic agents, and future prospects. Etc. will be introduced.
Related articles (from JAG NTD's past news articles)
- [Webinar] Notice of Completion of the Pediatric Praziquantel Consortium's pivotal Phase III trial
- [News] Phase III study of schistosomiasis pediatric formulation "Arapraziquantel" by the pediatric Praziquantel Consortium has been completed. Good results are obtained in terms of efficacy and safety.